MonTa Biosciences will be presenting very strong data on our immuno oncology technology at the annual meeting of AACR in Orlando

MonTa Biosciences will be presenting very strong data on our immuno oncology technology with our [...]

MonTa Biosciences open clinical sites in Madrid and Bruxelles

MonTa Bisciences have in January opened additionally 4 clinical sites in Madrid and Bruxelles. We [...]

MonTa Biosciences Announces Investment to Complete the Ongoing Phase I Monotherapy Trial on MBS8, and a Combination Phase IB/IIA Trial with MBS8 and a Currently Approved Oncology Drug.

COPENHAGEN, Denmark, October 20, 2022 — MonTa Biosciences, a clinical-stage biotechnology company focused on stimulating [...]

MonTa Biosciences featured in Nature pharmadealmakers magazine

MonTa Biosciences was featured as an upcoming biotech oncology company in Natures edition of pharmadealmakers. [...]

MonTa Biosciences successfully dose first patient in phase I clinical trial

MonTa Biosciences this week successfully enrolled and dosed the first cancer patient in our phase [...]

MonTa Biosciences awarded approval from regulatory agencies to start phase I study

MonTa Biosciences was awarded with positive feedback from the regulatory agency in Denmark to initiate [...]

MonTa Biosciences becomes a Clinical Stage Company

MonTa Biosciences today announced that the company has transitioned from a preclinical to a Clinical [...]

MonTa Biosciences initiates collaboration with NCI under the Nanotechnology Characterization Laboratory program

MonTa Biosciences has successfully gone through a tough selection process and been enrolled into the [...]

MonTa Biosciences successfully completed regulatory advice meeting with the Danish Medicines Agency

MonTa Biosciences have completed our regulatory meeting with the Danish Medicines Agency to align views [...]

MonTa Biosciences recruits Chief Medical Officer Steven Glazer to bring MonTas lead candidate MBS8 into clinical development

Steven Glazer is a well renowned clinical expert and biotech entrepreneur who has a strong [...]

MonTa Biosciences close a Series A investment from existing investors to complete phase I in cancer patients

MonTa Biosciences announced completion of a Series A investment from existing investor Consolidated Biosciences Aps [...]

Selected as an alumni case in the Nordic Mentoring Programme

MonTa Biosceinces was selected among successful biotech startups in the Nordic Mentoring Programme as an [...]

Attending the BioEurope conference in Hamburg

MonTa Biosciences is attending the BioEurope conference in Hamburg to meet with biotech and pharma companies [...]

Presenting data at the cancer immunotherapy SITC conference

MonTa Biosciences is attending the cancer immunotherapy SITC conference in Washington DC to present data on our [...]

Meeting with Key Opinion Leaders to plan phase I trial in patients

MonTa Biosciences attends the ESMO conference in Barcelona to meet with Key Opinion Leaders to [...]

Fireside interview at the IP-FAIR conference

MonTa Biosciences is invited to a fireside interview at the IP-FAIR conference in Copenhagen on May 8. [...]

Pharma business conference BioEurope in Vienna

MonTa Biosciences join the pharma business conference BioEurope in Vienna to meet with pharma and biotech [...]

Investment with Consolidated Holdings

MonTa Biosciences closes investment with Consolidated Holdings to secure future development towards clinical trials. Link [...]

Invitation to speak and join panel discussion at the NLSDays

MonTa Biosciences is invited to speak and join panel discussion with major Big Pharma companies Roche [...]

MonTa Biosciences attend Bio in Boston

MonTa Biosciences attend Bio in Boston from June 4-7th to meet and discuss partnership, collaborations and investment opportunities. Send [...]